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The Calcium-Sensing Receptor and
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Arthur D. Conigrave*
Faculties of Science and Medicine, School of Life and Environmental Sciences, Charles Perkins Centre, University of Sydney,
Sydney, NSW, Australia
Parathyroid hormone (PTH) defends the extracellular fluid from hypocalcemia and has
powerful and well-documented actions on the skeleton and renal tubular system. To
achieve a satisfactory stable plasma calcium level, the secretion of PTH, and the resulting
serum PTH level, is titrated carefully to the prevailing plasma ionized Ca2+ concentration
via a Ca2+ sensing mechanism that mediates feedback inhibition of PTH secretion.
Herein, I consider the properties of the parathyroid Ca2+ sensing mechanism, the identity
of the Ca2+ sensor, the intracellular biochemical mechanisms that it controls, the manner
of its integration with other components of the PTH secretion control mechanism, and
its modulation by other nutrients. Together the well-established, recently elucidated, and
yet-to-be discovered elements of the story constitute the past, present, and future of the
parathyroid and its calcium-sensing receptor (CaSR).
Keywords: calcium-sensing receptor, parathyroid, phospholipase C, adenylate cyclase, heterotrimeric G proteins,
Calcimimetics, calcilytics, mineral metabolism
INTRODUCTION
The parathyroid gland elaborates a peptide hormone, parathyroid hormone (PTH) whose primary
role is to prevent and/or reverse acute hypocalcemia. It achieves this by: mobilizing calcium
from stores in bone; stimulating renal Ca2+ reabsorption; and promoting the production of 1,25-
dihydroxyvitamin D3 to drive intestinal calcium absorption. To prevent uncontrolled elevations
in plasma calcium concentration in response to PTH, a molecular feedback mechanism mediated
by the extracellular Ca2+ ion concentration (Ca2+o) suppresses PTH secretion from the cells
of the gland (review: Conigrave and Ward, 2013). While this mechanism operates primarily on
parathyroid chief cells, which are the most numerous cell type and major site of PTH production,
it may also operate on a second less numerous cell type, the parathyroid oxyphil cells (Ritter et al.,
2012). In addition to providing acute control of PTH secretion from both newly-formed secretory
vesicles and stored secretory granules, the Ca2+-mediated feedback mechanism also suppresses
the transcription of the PreProPTH gene and cell proliferation (review: Brown and MacLeod,
2001). Herein, I provide an account of how the pivotal parathyroid Ca2+ sensing mechanism was
first characterized and how key biochemical features of the signaling mechanisms were exploited
to clone the class C G-protein coupled receptor (GPCR) we now know as the calcium-sensing
receptor (CaSR). I go on to describe how studies of this receptor in these cells have led to deep
understandings of parathyroid function in health and disease and new approaches to therapies for
various disorders of calcium metabolism and parathyroid function.
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THE PAST
In vivo and In vitro Evidence for a
Parathyroid Ca2+ Sensing Mechanism
Surgical removal of the parathyroid glands, whether intentional
or inadvertent, induces acute, and in some cases catastrophic,
hypocalcemia in experimental animals and in humans (e.g.,
MacCallum and Voegtlin, 1909; MacCallum et al., 1914;
Westerdahl et al., 2000; Vasher et al., 2010; Salinger and Moore,
2013). In addition, perturbations of the plasma ionized calcium
concentration in vivo by intravenous infusions of calcium salts to
induce hypercalcemia or Ca2+ chelators such as citrate or EGTA
to induce hypocalcemia provoke rapid negative and positive
changes in the serum PTH concentration respectively (Fox and
Heath, 1981; Conlin et al., 1989; Schwarz et al., 1992). These
studies demonstrate that the gland is equipped with a Ca2+-
sensor that suppresses PTH secretion in response to elevated
Ca2+ concentration.
The successful preparation of bovine parathyroid cells
using collagenase digestion of sliced parathyroid gland tissue
provided novel opportunities to assess the cellular Ca2+ sensing
mechanism in vitro (Brown et al., 1976) and similar observations
were made for porcine (Morrissey and Cohn, 1978) and also
human (Birnbaumer et al., 1977; Brown et al., 1978a, 1979a;
Conigrave et al., 2004) parathyroid cells. In all these cases,
mammalian parathyroid cells in primary culture supported
a robust endogenous secretion of PTH that was promptly
shut off upon elevation of Ca2+o. In cells prepared from
samples of parathyroid tissue derived from patients with primary
hyperparathyroidism there was impairment but not complete
loss of Ca2+o sensitivity (Brown et al., 1979a,c; Mun et al., 2009).
The behavior raises questions about the nature of the extracellular
Ca2+ sensor. It also raises questions about the nature of the
intrinsic/endogenous PTH secretion mechanism.
In the first description of a viable, functional parathyroid
cell preparation (Brown et al., 1976) bovine parathyroid cells
in primary culture in Eagle’s medium (minus bicarbonate)
secreted PTH linearly at a rate of 20–30 pmol cell−1 h−1
for up to 3 h. PTH secretion was suppressed by around 60%
at a Ca2+o of 1.5mM when compared to that observed at
0.5mM Ca2+o. In the presence of 0.5mM Ca
2+
o, elevated
extracellular Mg2+ concentration (Mg2+o) also suppressed PTH
secretion although Mg2+o was less potent than Ca
2+
o. Finally,
increases in PTH secretion were observed in response to the β-
adrenergic agonist isoproterenol that were partially reversed by
the β-adrenergic antagonist propranolol (Brown et al., 1976).
Thus, key features of the preparation included: Ca2+o- and
Mg2+o-mediated suppression of PTH secretion, pointing to
the existence of an intrinsic divalent cation sensor with a
preference for Ca2+o over Mg
2+
o; and stimulation of PTH
secretion by cAMP-linked GPCRs including beta-adrenergic,
dopaminergic, and prostanoid receptors (Brown et al., 1977a,b;
Gardner et al., 1980). These findings pointed to the existence
of neuronal, hormonal, and/or local stimulatory control of
PTH secretion. Although not clearly identified, the findings
also demonstrated the existence of an intrinsic PTH secretion
mechanism. According to one interpretation, parathyroid cells
are equipped with a constitutive PTH secretion mechanism.
According to an alternative interpretation, parathyroid cells
respond to an autocrine/paracrinemechanism that supports PTH
secretion.
The Concept of a Calciostat and an
Extracellular Ca2+ Set-Point
The Ca2+-sensing mechanism in the parathyroid supports the
operation of an extracellular “calciostat” in vivo. The set-point
for this calciostat occurs at a plasma ionized Ca2+ concentration
of around 1.1–1.2mM corresponding to plasma total calcium
concentrations of around 2.2–2.4mM, of which approximately
half is in an albumin-bound form. PTH secretion rates rise 2
to 4-fold as Ca2+o drops toward 1.0mM and are effectively
suppressed by >50% as Ca2+o rises toward 1.4mM (review:
Conigrave et al., 2000a). The changes in PTH secretion rate
are reflected in consonant changes in the serum PTH level
(normal range 1–6 pmol/L). This set-point behavior can be
readily demonstrated in perifused parathyroid cell preparations
including those prepared from human parathyroid glands
(Conigrave et al., 2004; Figure 1). Ca2+o-dependent inhibitory
control of renal Ca2+ reabsorption, resulting in elevated renal
calcium excretion, also contributes to the calciostat function,
providing a key element of the defense against hypercalcemia
(Kantham et al., 2009; Loupy et al., 2012).
Extracellular Ca2+-Mediated Signaling
Mechanisms
cAMP Promotes PTH Secretion via a Ca2+-Sensitive
Pathway
Suppression of cAMP levels accompanies high Ca2+o-induced
suppression of PTH secretion in parathyroid cells stimulated
to secrete by exogenous agonists of Gs-coupled GPCRs (Brown
et al., 1977a, 1979b, 1978b, 1985; Windeck et al., 1978) and
also in cells not exposed to exogenous GPCR activators, in
which intracellular cAMP levels are typically much lower (≤5%
of those in stimulated cells; Brown et al., 1978b). Excellent
correlations were observed between cAMP levels and PTH
secretion rates in these experiments supporting the hypothesis
that cAMP is a primary driver of both exogenous GPCR-
stimulated and intrinsic PTH secretion (Brown et al., 1978b).
Similar results were obtained in a comparative analysis of
the effects of divalent and tervalent cations on PTH secretion
and cAMP accumulation (Brown et al., 1990). If this is so,
the mechanisms of Ca2+o-dependent suppression of cAMP
levels and PTH secretion are different under the conditions
of (i) exogenous, GPCR-stimulated and (ii) spontaneous PTH
secretion. This follows because pertussis toxin disabled Ca2+o-
and divalent/tervalent cation-induced suppression of dopamine-
stimulated PTH secretion (Chen et al., 1989; Brown et al., 1990),
demonstrating that Gi is required for inhibitory control of PTH
secretion downstream of cAMP-linked GPCRs, but pertussis
toxin had no dis-inhibitory effect on high Ca2+o-mediated
suppression of intrinsic PTH secretion i.e., in the absence of
exogenous GPCR activators (Brown et al., 1992). Findings in
support of the hypothesis that pertussis toxin suppresses both
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FIGURE 1 | The calciostat in parathyroid cells. Left: A representation of the feedback mechanism by which PTH elevates the serum* Ca2+ concentration and
Ca2+ feeds back on the parathyroid to suppress PTH secretion in a process mediated by the CaSR. Right: Human parathyroid cells were perifused with
HEPES-buffered physiological saline solutions containing various Ca2+ concentrations and samples of perifusate were collected at various times and subsequently
analyzed for PTH1–84 as described in Conigrave et al. (2004). The results have been re-drawn. *Total and ionized calcium concentrations are comparable in serum
and plasma since the major calcium-binding protein, albumin is present in similar concentrations in both these fluids.
exogenous GPCR-stimulated and endogenous PTH secretion
(Fitzpatrick et al., 1986a) have not been confirmed.
The results suggest the existence of an extracellular Ca2+
sensor that is capable of activating Gi to suppress cAMP synthesis
and, in turn, cAMP-linked PTH secretion in the presence of
exogenous agonists that markedly elevate cAMP levels. The lack
of association between Gi, cAMP levels, and PTH secretion in
parathyroid cells NOT exposed to exogenous GPCR activators,
on the other hand, points to a distinct biochemical mechanism
arising either from a second Ca2+ sensor or from a single Ca2+
sensor that couples to distinct downstream signaling pathways
depending on whether the cells have been stimulated to secrete
PTH by exogenous activators or are operating spontaneously
(Figure 2). Support for the hypothesis that the Ca2+ sensing
mechanism in parathyroid cells is mediated by Ca2+ channels
and controlled by the activity of pertussis toxin-sensitive G-
proteins (Fitzpatrick et al., 1986a,b) has not been supported
by other studies (e.g., Brown et al., 1992). More recent work
has implicated Gq/11 and, possibly, phosphatidylinositol-specific
phospholipase C (PI-PLC) and ERK1/2 downstream of an
extracellular Ca2+ sensing GPCR (see below).
Intracellular Ca2+ Mobilization and PI-PLC
An alternative signaling pathway, downstream of an extracellular
Ca2+ sensor was subsequently identified in populations of bovine
parathyroid cells loaded with the cell-permeant Ca2+-sensitive
fluorophore fura-2AM. The cells exhibited robust intracellular
Ca2+ transients in response to elevated Ca2+o suggesting the
action of a PI-PLC coupled GPCR that senses increases in Ca2+o
(Nemeth and Scarpa, 1986, 1987a). Furthermore, they exhibited
similar intracellular Ca2+ transients in response to elevated
Mg2+ or Sr2+ concentration consistent with the observations
referred to above that the parathyroid Ca2+ sensing mechanism
is promiscuous with respect to divalent cations (Chen et al., 1989;
Brown et al., 1990). To investigate whether the parathyroid Ca2+
sensor might indeed be a PI-PLC coupled GPCR, further studies
demonstrated that Ca2+, Mg2+ and other inorganic divalent
cations promoted the production of water-soluble [3H]-inositol
phosphates from [3H]-inositol labeled cells (Brown et al., 1987;
Shoback et al., 1988).
A Promiscuous Divalent/Multivalent Cation
Sensor
Investigation of the molecular requirements for divalent
cation sensing in parathyroid cell preparations led to some
surprising observations. Firstly, tervalent inorganic cations of the
lanthanide group including Gd3+ and Tb3+ were found to be
high potency activators (EC50 ≈ 5–50µM) of parathyroid PI-
PLC, suppressors of GPCR-stimulated cAMP accumulation, and
inhibitors of PTH secretion (Brown et al., 1990) in a manner
analogous to divalent cations. Furthermore, and even more
surprisingly, organic multivalent cations including polyarginine,
polylysine, and protamine (Brown et al., 1991a), the PLC
inhibitor neomycin (Brown et al., 1991b), and polyamines such
as spermine (Nemeth and Scarpa, 1987b) stimulated intracellular
Ca2+ mobilization and inhibited PTH secretion.
Expression Cloning of a Polyvalent
Cation-Sensing Receptor from a Bovine
Parathyroid cDNA Library
The demonstration that the parathyroid calcium sensor coupled
to the activation of PI-PLC and, at least in certain circumstances,
to heterotrimeric Gi G-proteins, and was promiscuous with
respect to inorganic and organic multivalent cations provided
a strategy by which a putative PLC-coupled receptor might be
cloned by cellular expression of pools of mRNA derived from
a size-fractionated bovine parathyroid cDNA library (Brown
et al., 1993). Xenopus oocytes express a large conductance Cl−
channel whose open probability is highly sensitive to changes
in intracellular Ca2+ concentration (e.g., downstream of GPCR-
mediated generation of IP3 and intracellular Ca
2+ mobilization).
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FIGURE 2 | Stimulated and spontaneous mechanisms in support of
PTH secretion and its inhibition by high Ca2+o. PTH secretion and its
inhibition by high Ca2+o arises from two distinct mechanisms. One
mechanism is supported by exogenous agonists, including neurotransmitters
or hormones, that activate Gs-coupled GPCRs as shown in (A) (left and right).
PTH secretion continues provided Ca2+o remains low but is promptly inhibited
by Gi-dependent inhibition of adenylate cyclase in the presence of high
Ca2+o. The mechanism by which the Ca
2+
o sensor, now known to be the
CaSR, preferentially binds to Gi in this context is not known but might depend
on local protein kinase-A (PK-A) activation. A second mechanism occurs
spontaneously and may be supported by constitutive Gs-coupled GPCR
activity (as shown in B; left and right) or by autocrine/paracrine production of
receptor activators. PTH secretion via this second mechanism continues
provided Ca2+o remains low but is inhibited by high Ca
2+
o-induced
Gq/11-dependent activation of intracellular Ca
2+ mobilization or Ca2+ influx
(not shown). One possible mechanism by which increased intracellular free
Ca2+ concentration (Ca2+ i) suppresses PTH secretion is shown via
Ca2+ i-dependent inhibition of adenylate cyclase. *Receptor activated in the
absence of neuronal or hormonal stimuli.
In this case, the successful cloning of the novel class C GPCR
that is now referred to as “the calcium-sensing receptor” relied
on its high degree of sensitivity to Gd3+, which was used to
identify “active” pools of mRNA for further separation and
purification. Once cloned, the receptor was readily expressed
not only in Xenopus oocytes but also various mammalian
cell lines including HEK-293 cells and was found to exhibit
sensitivity not only to divalent inorganic cations including Ca2+
and Mg2+, and tervalent inorganic cations including Gd3+
but also to organic cations including the antibiotic neomycin
(Brown et al., 1993), polyamines such as spermine (Quinn
et al., 1997), cationic polypeptides such as polyarginine and
polylysine (Ray and Northup, 2002), and cationic proteins
including beta amyloid (Ye et al., 1997). The cloning of the bovine
parathyroid CaSR was followed subsequently by the cloning of
its orthologs from human parathyroid (Garrett et al., 1995),
rat kidney (Riccardi et al., 1995), and rat brain (Ruat et al.,
1995).
The CaSR is known now to be expressed widely, with various
Ca2+o-dependent and non-Ca
2+
o dependent functions in cell
and developmental biology as detailed elsewhere in this issue. It
is also known to activate a large number of signaling pathways
downstream of various G-proteins and multiple cell membrane-
associated as well as cytoplasmic enzymes (review: Conigrave and
Ward, 2013).
The CaSR mediates, for example, the activation of various
protein kinases including protein kinase C isoforms, which
negatively modulate CaSR function (Jiang et al., 2002; Davies
et al., 2007; Lazarus et al., 2011; Young et al., 2014), and the
mitogen activated protein (MAP) kinases ERK1/2, p38 and JNK
(Kifor et al., 2001; Tfelt-Hansen et al., 2003; review: Conigrave
and Ward, 2013). The roles of protein kinases in CaSR-mediated
inhibitory control of PTH secretion are not well-understood but
ERK1/2 appears to contribute (Corbetta et al., 2002) and could
be activated downstream of either Gq/11 or Gi (review: Conigrave
and Ward, 2013).
While the CaSR is expressed and trafficked to the plasma
membrane as functional homodimers (Bai et al., 1998, 1999)
that couple efficiently to Gq/11, it is also capable of forming
heterodimers with other members of GPCR family C including
metabotropic glutamate receptors (Gama et al., 2001) and
GABAB receptors, especially GABAB1 (Chang et al., 2007; Cheng
et al., 2007). The consequences of heterodimerization for receptor
localization to specific subdomains of the plasma membrane and
for signaling pathway selection in different tissues and for the
parathyroid, in particular, are not yet clear.
Physiological and Clinical Significance of
the CaSR for Parathyroid Function
Parathyroid and Mineral Disorders Linked to CaSR
Mutations (and Anti-CaSR Antibodies)
As the bovine parathyroid, rat kidney, and human parathyroid
CaSR cDNAs were cloned (Brown et al., 1993; Garrett et al.,
1995; Riccardi et al., 1995), it became possible to assess whether
any recognized human disorders of calcium metabolism and/or
parathyroid function arose from mutations of the CaSR. This
was rapidly confirmed for two hypercalcemic disorders in which
the CaSR is hypofunctional: the uncommon disorder known as
familial hypocalciuric hypercalcemia (FHH); and the extremely
rare disorder known as neonatal severe hyperparathyroidism
(NSHPT; Pollak et al., 1993, 1994; reviews: Brown et al.,
1995; Hendy et al., 2000). It was subsequently also confirmed
for the hypocalcemic disorder known as autosomal dominant
hypocalcemia (ADH; Pearce et al., 1996) in which the CaSR is
hyperfunctional.
FHH
Deactivating, typically heterozygous, mutations of the CaSR
gene in FHH result in impaired or disabled Ca2+o-dependent
inhibition of renal Ca2+ reabsorption, leading to hypocalciuria,
and as well as impaired Ca2+o-dependent feedback inhibition
of PTH secretion, typically without frank elevations in the
serum PTH level as a result of associated increases in Ca2+o
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(Chu et al., 1995; review: Brown et al., 1995). Instead, the set-
point for Ca2+o-dependent suppression of PTH secretion rises
thereby increasing the value of the calciostat and the steady-
state Ca2+o adopts this new level. The primary driver for
the increase in Ca2+o appears to be impaired renal calcium
excretion, resulting in characteristic hypocalciuria (uCa/Cr ratio
< 0.04mmol mmol−1; uCa excretion < 1.5mmol d−1). With the
identification of two variants of FHH arising from mutations of
two other genes, Gα11 and AP2S (see below), the major form of
FHH that arises from mutations of the CaSR has been recently
renamed FHH1.
NSHPT
In contrast to FHH, homozygous or compound heterozygous
deactivating mutations of the CaSR gene have been linked to a
severe hypercalcemic disorder that presents in neonatal life with
total plasma calcium concentrations that may exceed 4.0mM
(Ward et al., 2004). In addition, there are marked elevations in
the serum PTH level, indicative of near-total failure of Ca2+o-
mediated feedback control of PTH secretion along with skeletal
demineralization and pathological fractures (Pollak et al., 1993;
review: Brown et al., 1995). The disorder responds promptly
to total parathyroidectomy i.e., excision of all four parathyroid
glands (Marx et al., 1986) demonstrating that the bone disease is
driven by severe primary hyperparathyroidism.
Whether still more severe disorders of skeletal development
and metabolism might arise from other types of CaSR mutations
is not yet clear. Recently developed mouse models, however,
suggest that this is so (Chang et al., 2008; Richard et al., 2010;
reviews: Goltzman and Hendy, 2015; Santa Maria et al., 2016).
An authoritative database of CaSR mutations and their links to
human disease is maintained at: http://www.casrdb.mcgill.ca/.
ADH
Two other rare mineral disorders affecting the parathyroid
arise from activating mutations of the CaSR. In one,
autosomal dominant hypocalcemia, there is hypocalcemia
and inappropriately normal or frankly low serum PTH levels
arising from a reduction in the set-point for extracellular Ca2+
(Pearce et al., 1996). One or more of the following may also be
observed: hypercalciuria, consistent with enhanced inhibition
of renal Ca2+ reabsorption; hypocalciuria (e.g., Tan et al.,
2003), consistent with reduced glomerular filtration of Ca2+
ions and a largely intact renal Ca2+ reabsorption mechanism;
hypomagnesemia; and hyperphosphatemia (reviews: Thakker,
2004; Egbuna and Brown, 2008). This is typically a chronic
benign condition, often diagnosed as an incidental finding
on plasma biochemical analysis, in which there may be a
longstanding history of paresthesiae, intermittent fasciculations
and/or contractions of isolated muscle groups. There may also
be a history of one or more childhood seizures including febrile
convulsions (reviews: Thakker, 2004; Egbuna and Brown, 2008).
In a second disorder, arising from more severe activating
mutations of the CaSR, a form of renal salt wasting also occurs.
This Bartter Syndrome (type-5) arises from unrestrained CaSR
activation on the contraluminal membrane of the thick ascending
limb, which disables NKCC2-dependent NaCl reabsorption
(reviews: Gamba and Friedman, 2009; Riccardi and Brown,
2010).
The impact of gene dosage on the severity of autosomal
dominant hypocalcemia has been evaluated in a mouse model,
the Nuf mouse (L723Q, affecting a residue at the C-terminal
end of iL-2), which exhibits hypocalcemia, suppressed serum
PTH levels, hypocalciuria, hyperphosphatemia, and ectopic
mineralization and cataracts (Hough et al., 2004). All aspects of
the phenotype were more severe in homozygous when compared
to heterozygous mice demonstrating that a gene dosage effect
applies in the case of activating as well as inactivating mutations
of the CaSR, and it is notable that renal hypophosphaturia
occurred in homozygous but not heterozygous Nuf mice
consistent with the idea that the CaSR normally suppresses
renal phosphate excretion including PTH-induced inhibition
of phosphate reabsorption (Riccardi et al., 2000; Ba et al.,
2003; reviews: Riccardi and Valenti, 2016) and thus promotes
phosphate retention. The disorder is amenable to treatment with
negative modulators of the CaSR, also known as calcilytics (see
below; Mayr et al., 2016; Nemeth and Goodman, 2016).
Disorders of Calcium Metabolism Arising from
Autoantibodies that Target the CaSR
In addition to the impact of inactivating or activating CaSR
mutations on calcium metabolism and parathyroid function as
described above, several studies have drawn attention to the
clinical impact of autoantibodies that target the CaSR with
either inactivating (Kifor et al., 2003; Pallais et al., 2004) or
activating (review: Brown, 2009) effects, presumably dependent
on the peptide epitope that is recognized. These autoimmune
disorders of calcium metabolism resemble other autoimmune
endocrinopathies such as Grave’s disease (review: Thakker,
2004). In one of these disorders associated with autoimmune
polyendocrinopathy, autoantibodies to several CaSR epitopes
have been identified corresponding to residues 41–69 at the
receptor’s N-terminus, 114–126 at the dimer interface, and 171–
195 in the vicinity of the Venus FlyTrap (VFT) domain’s binding
cleft (Kemp et al., 2010).
Transgenic Mouse Models—Impact of
Inactivating CaSR Mutations on
Parathyroid Function
The first reported transgenic mouse in which the CaSR was
“knocked out,” was homozygous for a 20 bp insertion that
disabled incorporation of CaSR exon-5 (referred to as CaSR
exon-4 in the paper) into the mature, fully processed mRNA
(Ho et al., 1995). CaSR exon-5 encodes residues 465–536
(http://www.casrdb.mcgill.ca) at the extreme C-terminal end of
the VFT domain, immediately prior to the start of the Cysteine-
rich domain. Mice with this genotype exhibited a condition
comparable to NSHPT in which homozygotes were normal at
birth but exhibited severe growth retardation and markedly
reduced muscle power in the days after birth (Ho et al., 1995).
The results of biochemical analyses demonstrated the
cardinal features of primary hyperparathyroidism including
markedly elevated plasma Ca2+ concentration, suppressed
plasma inorganic phosphate concentration, and markedly
elevated serum PTH levels. In addition, the parathyroid glands
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were enlarged with prominent chief cell hyperplasia (Ho et al.,
1995). These findings are consistent with a severe resistance
syndrome arising from markedly impaired Ca2+-dependent
feedback control of PTH secretion i.e., with loss of the
parathyroid Ca2+ sensor.
Heterozygotes, unlike the homozygotes, were phenotypically
normal in the weeks and months after birth but exhibited
mild biochemical disturbances consistent with FHH in
humans including mildly elevated plasma Ca2+ concentration,
suppressed renal calcium excretion, and inappropriately normal
plasma PTH levels. These findings suggest a mildly impaired
but intact parathyroid Ca2+ sensing mechanism together with
impaired extracellular Ca2+-dependent inhibition of renal Ca2+
reabsorption resulting in an increase in the setpoint of the
calciostat.
Is the Parathyroid Equipped with an
Alternative Calcium-Sensing Receptor?
While other class C GPCRs, like the CaSR, exhibit Ca2+-sensing
properties (Kubo et al., 1998; Wise et al., 1999; Christiansen
et al., 2007) it seems unlikely that the parathyroid is equipped
with an alternative CaSR since, as described above, mice that
are homozygous for either global (Ho et al., 1995) or tissue-
selective (Chang et al., 2008) knockouts of the CaSR exhibit a
severe, uncompensated form of primary hyperparathyroidism
in which the plasma levels of both PTH and calcium are
markedly elevated from birth. The phenotype suggests a
marked impairment of Ca2+o-dependent negative feedback on
PTH secretion with attendant hyperparathyroidism and PTH-
dependent bone resorption. Thus, if the parathyroid expresses
an alternative or supplementary calcium sensor, it is unable
to compensate for loss of the CaSR. It is possible that under
some circumstances Ca2+-sensing is mediated not by CaSR
homodimers but by CaSR heterodimers involving othermembers
of GPCR family C including metabotropic glutamate receptors
or GABAB1 receptors as noted above (Gama et al., 2001; Chang
et al., 2007; Cheng et al., 2007).
Previous work suggested a role for Ca2+-permeable channels
in the control of PTH secretion based on observations that
stereoisomers of the Ca2+ channel modulator 202–791 either
inhibited (+202 to 791) or stimulated (−202 to 791) PTH
secretion (Fitzpatrick et al., 1986b), and antibodies that target
skeletal muscle Ca2+ channels also modulated PTH secretion
(Fitzpatrick et al., 1988). Other Ca2+ channel activators,
including maitotoxin (Fitzpatrick et al., 1989), and the diltiazem
analog TA-3090 (Chen and Brown, 1990) were also found to
inhibit PTH secretion. This work was “turned on its head”
by the successful development of “calcimimetics” by structural
modification of an L-type Ca2+ channel blocker, fendiline
(Nemeth et al., 1998), and the subsequent demonstration that
modulation of PTH secretion by these agents arises not from
actions on Ca2+ channels but rather the cloned CaSR (Nemeth
et al., 2004; review: Nemeth, 2006). Thus, various agents that
modulate Ca2+ channel activity can also interact with an
allosteric site in the CaSR’s heptahelical domain (Leach et al.,
2016). Calcimimetics, positive modulators of the CaSR, and
calcilytics, negative modulators of the CaSR, are discussed in
greater detail below.
Nevertheless, more recent work raises the possibility that
Ca2+-permeable channels may indeed contribute to the control
of PTH secretion. Thus, parathyroid cells express NMDA
receptor subunits and NMDA inhibits PTH secretion (Parisi
et al., 2009). While these receptors may contribute to the tonic
control of PTH secretion, it is not known whether Ca2+ fluxes
arising from the activation of NMDA receptors are sensitive to
Ca2+o concentration in parathyroid cells. In addition, various
amino acids and amino acid analogs are known to interact with
the CaSR (Conigrave et al., 2000b, 2004; review: Conigrave and
Hampson, 2010) and it is not yet clear whether the inhibitory
effect of NMDA on PTH secretion is exerted by the activation of
Ca2+-permeable ion channels or via positive modulation of the
CaSR.
THE PRESENT
Development of Calcimimetics and Their
Utility in Several Forms of
Hyperparathyroidism
As noted above, calcimimetics were developed from the Ca2+
channel blocker fendiline that induces Ca2+i mobilization
and suppresses PTH secretion from bovine parathyroid cells
(Nemeth et al., 1998; review: Nemeth, 2006). Drug development
resulted in a new class of pharmaceuticals, the phenylalkylamine
calcimimetics, which are positive allosteric modulators of the
CaSR that markedly enhance the sensitivity of CaSR-mediated
intracellular signaling pathways to Ca2+o (Nemeth et al.,
1998). Early examples included NPS R467 and NPS R568,
which together with their less potent S-isomers have been key
agents for the analysis of CaSR-mediated effects in various cell
and tissue systems. More recent examples include cinacalcet,
an agent that is well-absorbed orally (Nemeth et al., 2004)
and is effective clinically in the treatment of both secondary
hyperparathyroidism due to chronic kidney disease (Moe et al.,
2005; Messa et al., 2008) as well as primary hyperparathyroidism
(Peacock et al., 2005, 2011; see also review: Nemeth and Shoback,
2013).
One key effect of calcimimetics is suppression of the serum
PTH level. In primary hyperparathyroidism, for example, in
which the plasma total calcium concentration is typically elevated
from its normal upper limit of 2.6 mM to around 2.8–3.0 mM,
oral therapy with cinacalcet suppressed serum PTH levels and
restored the plasma calcium concentration into the normal range
for up to 12 months or more (Peacock et al., 2005). Another key
effect is suppression or even reversal of parathyroid hyperplasia.
For example, cinacalcet suppresses parathyroid cell proliferation
and reduces gland size in models of primary (Imanishi et al.,
2011) and secondary (Colloton et al., 2005; Miller et al., 2012)
hyperparathyroidism, and also induces apoptosis in second
hyperparathyroidism (Tatsumi et al., 2013).
The demonstration that calcimimetics from the same class
and across different classes exhibit different biased signaling
profiles (Davey et al., 2012) is encouraging efforts to develop
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new generation calcimimetics in support of tissue-specific
CaSR-targeted pharmacotherapy e.g., parathyroid vs. kidney vs.
thyroid C-cells (review: Leach et al., 2015). Recent modeling
of calcimimetic binding in the CaSR’s heptahelical domain
suggests that agents such as A265347 with less pronounced biased
signaling profiles may bind more deeply in the allosteric pocket
(Leach et al., 2016).
More recently, a peptide activator of the CaSR (AMG-416;
L-Cys-AcDCys-DAla-(DArg)2-DAla-DArgNH2) has entered
clinical practice for the treatment of patients with secondary
hyperparathyroidism on hemodialysis (Bell et al., 2015).
Administered intravenously it has superior pharmacokinetics
including effective suppression of PTH levels beyond 24 h
(Walter et al., 2013) due, presumably, to its ability to form a
di-sulfide with CaSR residue C482 in its extracellular domain
(Alexander et al., 2015).
Calcilytics
Several classes of calcilytics (negative modulators of the CaSR)
have been developed. These agents, in general, bind in the HH
domain and suppress CaSR signaling. For this reason, they have
proved useful in assessing the role of the CaSR in Ca2+- or L-
amino acid-induced cellular or tissue responses (e.g., Dvorak
et al., 2004; Daly et al., 2013). In the parathyroid, calcilytics
promote PTH secretion by reversing the inhibitory action of the
CaSR (Nemeth et al., 2001). As a consequence, it was hoped that
these agents might prove useful in the treatment of osteoporosis
by elevating serum PTH levels to emulate the action of
intermittent subcutaneous injections of PTH1–34 (teriparatide).
However, none of the calcilytics that have entered human clinical
trials, thus far, have been successful in significantly increasing
bone density or reducing fracture risk (review: Nemeth and
Goodman, 2016). Two main explanations seem reasonable:
(i) the maximum increase in the serum level of endogenous
PTH is significantly less than that achieved by subcutaneous
injections of PTH1–34 (e.g., Kimura et al., 2011); or (ii) calcilytics
suppress CaSRs in cells of the osteoblast lineage to interfere with
PTH-induced cell maturation and key differentiated functions
including matrix synthesis and mineralization (Dvorak et al.,
2004).
Nutrient Activators of the CaSR
In addition to its regulation by Ca2+ ions, the CaSR also responds
promiscuously to L-amino acids of various classes (Conigrave
et al., 2000b), and one of the most potent, L-Trp, has been shown
recently to bind in the receptor’s VFT domain ligand-binding
groove (Geng et al., 2016; see below). This behavior resembles
that of several class C GPCRs (Conigrave and Hampson,
2006, 2010) and supports macronutrient sensing in various
tissues including the gastrointestinal tract (review: Conigrave
and Brown, 2006). Based on the signaling pathway analysis
performed to date, however, Ca2+o and L-amino acids are not
equivalent activators. In particular, L-amino acids preferentially
activate a Ca2+i mobilizing pathway and have more limited
actions on PI-PLC and ERK1/2 (review: Conigrave and Ward,
2013). Nevertheless, L-amino acids are potent activators of
Ca2+i mobilization in parathyroid cells and also suppress PTH
secretion at physiologically relevant concentrations (Conigrave
et al., 2004). Furthermore, glutathione and various analogs
(e.g., S-methylglutathione) also activate Ca2+i mobilization and
suppress PTH secretion, presumably by binding to the same VFT
domain ligand-binding groove (Broadhead et al., 2011). These
findings imply that protein nutritional state is negatively coupled
to the control of PTH secretion and thus serum PTH levels. The
full significance of these effects, however, is not yet known (see
below).
Control of CaSR Gene Expression
Analysis of the promoter regions of the CaSR gene has led to the
identification of two key positive modulators of expression: (i)
inflammatory cytokines including IL-1β, IL-6 and TNFα (Canaff
and Hendy, 2005); and (ii) hormonally active analogs of vitamin
D including 1,25-dihydroxyvitamin D3 (Canaff and Hendy,
2002), and possibly 25-hydroxyvitamin D3, whose plasma levels
are nearly 1000-fold higher. These results suggest that CaSR
expression may be upregulated in the parathyroid and other
CaSR-expressing tissues in response to various inflammatory
conditions and in response to elevations in either serum 1,25-
dihydroxyvitamin D3 or 25-hydroxyvitamin D3 levels.
RECENT DEVELOPMENTS AND THE
FUTURE
G-Protein Coupling
The CaSR couples to various G-proteins (review: Conigrave
and Ward, 2013). Notable from the perspective of parathyroid
function are Gi, which suppresses agonist-stimulated GPCR-
mediated cAMP production and contributes to the activation
of ERK1/2 at least in part via β-arrestin, and Gq/11, which
activates PI-PLC and induces Ca2+i mobilization, with attendant
activation of several protein kinase C isoforms and ERK1/2.
Both the Gi andGq/11 pathways appear to be important for the
inhibitory control of PTH secretion. With respect to Gq and G11,
it is now known that Gαq and Gα11 are required for the normal
control of PTH secretion. Thus, in a transgenic mouse in which
parathyroid-specific ablation of Gαq was produced on a global
Gα11 null background, severe neonatal hyperparathyroidism
was observed (Wettschureck et al., 2007) and resembled the
phenotypes of both global (Ho et al., 1995) and parathyroid-
specific (Chang et al., 2008) ablation of the CaSR. These findings
demonstrate that Gq and G11 are required for CaSR-mediated
control of PTH secretion and thus lie at the top of a key inhibitory
signaling pathway(s). Consistent with these findings, inactivating
and activating mutations of the human Gα11 gene have been
shown respectively to underlie variant forms of FHH (FHH2) and
ADH (ADH2; Nesbit et al., 2013a; Gorvin et al., 2016; Piret et al.,
2016).
Under certain circumstances, the CaSR also couples to Gs
(review: Conigrave and Ward, 2013) but the significance of this
pathway for the control of PTH secretion is unknown. It is
interesting to speculate that the “inactive” form of the receptor,
which is promoted under conditions of low Ca2+ and high
phosphate concentrations (Geng et al., 2016) might preferentially
couple to Gs in the parathyroid.
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Receptor Trafficking
Receptor trafficking studies have largely focused on cell systems
in which the CaSR is expressed heterologously (reviews:
Breitwieser, 2013, 2014). These studies demonstrate that
trafficking of the CaSR is modulated by various binding partner
proteins (review: Huang and Miller, 2007), can be promoted by
allosteric modulators such as cinacalcet and NPS-2143 acting as
pharmaco-chaperones (Leach et al., 2013), and is sensitive to
receptor-dependent signaling (Grant et al., 2011, 2012; review:
Breitwieser, 2012). In the parathyroid, the CaSR interacts with
caveolin and is thus likely to localize to sub-domains of the
plasma membrane known as caveolae (Kifor et al., 1998). In
addition, recent findings suggest that the CaSR is processed
between the plasma membrane and intracellular endosomes via
clathrin-coated vesicles since mutations of Arg15 of the sigma (σ)
subunit of the clathrin-binding protein AP2 have been linked to a
variant form of FHH, now known as FHH3 (Nesbit et al., 2013b).
The findings suggest that the formation, and/or maintenance,
of CaSR signaling complexes is impaired under conditions in
which clathrin-coated vesicle-mediated processing of the CaSR
is impaired.
X-ray Crystal Structures
While X-ray crystal structures of class C GPCR VFT domains
(Kunishima et al., 2000; Tsuchiya et al., 2002), entire extracellular
(VFT-plus-Cys-rich) domains (Muto et al., 2007), and even
heptahelical domains (Doré et al., 2014) have been reported over
the last 15 years, crystal structures for CaSR domains have only
recently become available (Geng et al., 2016; Zhang et al., 2016).
These newly described CaSR structures provide information
on the inactive and active forms of its VFT domain (Geng
et al., 2016; Zhang et al., 2016) and entire extracellular domain
(Geng et al., 2016). While the protein conformations of the
active forms of the VFT domain structures were almost identical,
the identification of divalent cation, and anion binding sites
were quite different in the structures reported by the two
groups. Zhang et al. (2016) identified just one Ca2+ site in
the active form of the VFT domain and relied on modeling
of electron densities to ascribe it to the ligand-binding cleft,
where it was closely associated with an L-amino acid-binding site.
Surprisingly, however, they identified a formaldehyde derivative
rather than the native form of L-Trp in the site.
In the structures described by Geng et al. (2016), on the
other hand, an anomalous mapping strategy was used to identify
four, previously unrecognized, Ca2+ binding sites, one of which
(“Site 2”) was present in both the inactive and active structures
and three of which were only identified in the active structure
and, thus, may act to stabilize it. Interestingly, no Ca2+ binding
site was located in the closed (active) form of the agonist-
binding cleft in the structure reported by Geng et al., which was
occupied instead by the amino acid L-Trp (Geng et al., 2016). In
addition, Geng et al. identified several binding sites for inorganic
phosphate in the inactive structure (Geng et al., 2016), raising
the possibility that not only the Ca2+o concentration but also
the ratio of Ca2+o to phosphate concentrations may control the
receptor’s transition between inactive and active states.
The findings that the receptor binds inorganic phosphate (Pi)
as well as Ca2+ ions and that Ca2+ stabilizes the active state,
whereas Pi stabilizes the inactive state have potentially important
implications for understanding parathyroid function since
elevated Pi concentrations stimulate PTH secretion (Slatopolsky
et al., 1996) whereas elevated Ca2+o inhibits it. Does the CaSR
modulate its response to Ca2+o according to the background
level of inorganic phosphate? Does the Ca:Pi ratio determine
PTH secretion rates by controlling the activation state of the
CaSR? Does the CaSR act as a phosphate sensor in other tissues
such as osteocytes or osteoblasts in bone?
Unresolved Problems
There are several unresolved problems. Four of them are
considered below in the form of sets of questions.
Question-Set 1
What drives intrinsic PTH secretion and how does the CaSR
suppress it in a Gi-independent manner? Is spontaneous PTH
secretion truly constitutive, implying that the pathway by which
PTH vesicles undergo exocytosis is unregulated? Alternatively,
is it promoted by receptors expressed on the surface of
parathyroid cells that are either constitutively active or exposed
to locally released activators such as histamine from mast cells or
prostanoids from chief or oxyphil cells?
Question-Set 2
What is the significance of amino acid-binding to the CaSR (Geng
et al., 2016) for parathyroid function? Does the parathyroid
CaSR read the local concentrations of L-amino acids arising from
export of amino acids from the cytoplasm or are they determined
by the amino acid concentrations in the bulk plasma. Does
amino acid sensing by the CaSR primarily affect PTH secretion
under conditions of protein deficiency and reductions in plasma
amino acid levels as suggested by the phenomenon of secondary
hyperparathyroidism in subjects on low protein diets (reviews:
Conigrave et al., 2002, 2008) or does it act primarily to suppress
PTH secretion under conditions of protein excess as suggested
by parathyroid cell responses in vitro (Conigrave et al., 2004).
Alternatively, might L-amino acid sensing by the CaSR provide
a mechanism for adjusting the inhibitory gain on the receptor to
the level of amino acid-dependent PTH synthesis?
Question-Set 3
What is the significance of CaSR heterodimerization for
parathyroid function? Is the parathyroid subject solely to control
by CaSR homodimers or are some Ca2+-dependent signaling
pathways (e.g., for the control of parathyroid chief cell number,
or PreProPTH gene expression) subject to control by CaSR
heterodimers with metabotropic glutamate receptors (Gama
et al., 2001) or GABAB1 receptors (Chang et al., 2007)?
Question-Set 4
Can CaSR expression be effectively upregulated in hypercalcemic
conditions such as primary hyperparathyroidism or FHH to
restore physiological control of plasma calcium levels and Ca2+o-
dependent suppression of PTH secretion? Can CaSR expression
be effectively downregulated in hypocalcemic conditions such as
ADH to restore physiological control of plasma calcium and PTH
levels? Can tissue-selective modulators of the vitamin D receptor
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or cytokine receptors, or other strategies, be developed for the
control of parathyroid CaSR expression?
CONCLUDING REMARKS
The role of the parathyroid in the whole body calcium economy
is so important that the negative feedback loop by which
PTH elevates plasma Ca2+ and Ca2+, in turn, suppresses
PTH secretion largely defines its place in human biology.
Expression cloning of the CaSR, its identification as the key
Ca2+ sensor of the parathyroid, and evaluation of its roles in
normal tissue biology and in human disease have resolved key
issues in calcium metabolism. New paradigms of Ca2+-mediated
control of tissue function and of the CaSR in macronutrient-
sensing have followed. Incredibly, the molecular mechanism
by which the CaSR suppresses PTH secretion is only partially
solved: for the situation in which PTH secretion is stimulated
by neurotransmitters or hormones that elevate cAMP levels.
The mechanisms by which the CaSR suppresses intrinsic PTH
secretion or the secretion of PTH downstream of hormones
that activate PTH secretion by non-cAMP pathways remain
undefined. Newly available X-ray crystal structures for the CaSR
extracellular domain in its inactive and active conformations
provide new opportunities to investigate the Ca2+ sensing
mechanism.
AUTHOR CONTRIBUTIONS
The author confirms being the sole contributor of this work and
approved it for publication.
FUNDING
The author’s work on the role of the calcium-sensing receptor
has been funded by the National Health & Medical Research
Council of Australia (project grants APP1011922, APP1026962,
and APP1085143).
ACKNOWLEDGMENTS
The author thanks Dr. Dorothea Szczawinska and Dr. Hee-
chang Mun for the opportunity to discuss several of the issues
relating to parathyroid biology that are considered in this
manuscript. He also thanks his current collaborators in the
field of calcium-sensing receptor biology including Dr. Donald
Ward of the University of Manchester, England UK, Prof Arthur
Christopoulos, and Dr. Katie Leach of the Monash Institute of
Pharmaceutical Sciences, Parkville, Victoria, Australia, and in
the field of parathyroid biology, Profs. Leigh Delbridge and Stan
Sidhu of the Department of Surgery, Royal North Shore Hospital,
St. Leonards, NSW, Australia.
REFERENCES
Alexander, S., Hunter, T., Walter, S., Dong, J., Maclean, D., Baruch, A., et al.
(2015). Critical Cysteine residues in both the calcium-sensing receptor and
the allosteric activator AMG 416 underlie the mechanism of action. Mol.
Pharmacol. 88, 853–865. doi: 10.1124/mol.115.098392
Ba, J., Brown, D., and Friedman, P. A. (2003). Calcium-sensing receptor regulation
of PTH-inhibitable proximal tubule phosphate transport. Am. J. Physiol. 285,
F1233–F1243. doi: 10.1152/ajprenal.00249.2003
Bai, M., Trivedi, S., and Brown, E. M. (1998). Dimerization of the extracellular
calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293
cells. J. Biol. Chem. 273, 23605–23610. doi: 10.1074/jbc.273.36.23605
Bai, M., Trivedi, S., Kifor, O., Quinn, S. J., and Brown, E. M. (1999). Intermolecular
interactions between dimeric calcium-sensing receptor monomers are
important for its normal function. Proc. Natl. Acad. Sci. U.S.A. 96, 2834–2839.
doi: 10.1073/pnas.96.6.2834
Bell, G., Huang, S., Martin, K. J., and Block, G. A. (2015). A randomized, double-
blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the
treatment of secondary hyperparathyroidism in hemodialysis patients. Curr.
Med. Res. Opin. 31, 943–952. doi: 10.1185/03007995.2015.1031731
Birnbaumer, M. E., Schneider, A. B., Palmer, D., Hanley, D. A., and Sherwood,
L. M. (1977). Secretion of parathyroid hormone by abnormal human
parathyroid glands in vitro. J. Clin. Endocrinol. Metab. 45, 105–113.
doi: 10.1210/jcem-45-1-105
Breitwieser, G. (2012). Minireview: the intimate link between calcium sensing
receptor trafficking and signaling: implications for disorders of calcium
homeostasis.Mol. Endocrinol. 26, 1482–1495. doi: 10.1210/me.2011-1370
Breitwieser, G. (2013). The calcium sensing receptor life cycle: trafficking, cell
surface expression, and degradation. Best Pract. Res. Clin. Endocrinol. Metab.
27, 303–313. doi: 10.1016/j.beem.2013.03.003
Breitwieser, G. (2014). Pharmacoperones and the calcium sensing receptor:
exogenous and endogenous regulators. Pharmacol. Res. 83, 30–37.
doi: 10.1016/j.phrs.2013.11.006
Broadhead, G. K., Mun, H. C., Avlani, V. A., Jourdon, O., Church, W. B.,
Christopoulos, A., et al. (2011). Allosteric modulation of the calcium-sensing
receptor by, γ-glutamyl peptides: inhibition of PTH secretion, suppression
of intracellular cAMP levels and a common mechanism of action with
L-amino acids. J. Biol. Chem. 286, 8786–8797. doi: 10.1074/jbc.M110.
149724
Brown, E. (2009). Anti-parathyroid and anti-calcium sensing receptor antibodies
in autoimmune hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 38,
437–445. doi: 10.1016/j.ecl.2009.01.001
Brown, E. M., Gardner, D. G., Brennan, M. F., Marx, S. J., Spiegel, A. M., Attie, M.
F., et al. (1979a). Calcium-regulated parathyroid hormone release in primary
hyperparathyroidism: studies in vitro with dispersed parathyroid cells. Am. J.
Med. 66, 923–931. doi: 10.1016/0002-9343(79)90446-7
Brown, E. M., Gardner, D. G., Windeck, R. A., Hurwitz, S., Brennan, M. F.,
and Aurbach, G. D. (1979b). Beta-adrenergically stimulated adenosine 3′,5′-
monophosphate accumulation in and parathyroid hormone release from
dispersed human parathyroid cells. J. Clin. Endocrinol. Metab. 48, 618–626.
doi: 10.1210/jcem-48-4-618
Brown, E. M., Hurwitz, S., and Aurbach, G. D. (1976). Preparation of
viable isolated bovine parathyroid cells. Endocrinology 99, 1582–1588.
doi: 10.1210/endo-99-6-1582
Brown, E. M., Hurwitz, S., and Aurbach, G. D. (1977a). Beta-adrenergic
stimulation of cyclic AMP content and parathyroid hormone release
from isolated bovine parathyroid cells. Endocrinology 100, 1696–1702.
doi: 10.1210/endo-100-6-1696
Brown, E. M., Brennan, M. F., Hurwitz, S., Windeck, R., Marx, S. J., Spiegel, A. M.,
et al. (1978a). Dispersed cells prepared from human parathyroid glands: distinct
calcium sensitivity of adenomas vs. primary hyperplasia. J. Clin. Endocrinol.
Metab. 46, 267–275. doi: 10.1210/jcem-46-2-267
Brown, E. M., Broadus, A. E., Brennan, M. F., Gardner, D. G., Marx, S. J., Spiegel,
A. M., et al. (1979c). Direct comparison in vivo and in vitro of suppressibility
of parathyroid function by calcium in primary hyperparathyroidism. J. Clin.
Endocrinol. Metab. 48, 604–610. doi: 10.1210/jcem-48-4-604
Brown, E. M., Butters, R., Katz, C., and Kifor, O. (1991b). Neomycin mimics the
effects of high extracellular calcium concentrations on parathyroid function in
dispersed bovine parathyroid cells. Endocrinology (Baltimore) 128, 3047–3054.
doi: 10.1210/endo-128-6-3047
Frontiers in Physiology | www.frontiersin.org 9 December 2016 | Volume 7 | Article 563
Conigrave Role of the CaSR in Parathyroid Function
Brown, E. M., Butters, R., Katz, C., Kifor, O., and Fuleihan, G. E. (1992). A
comparison of the effects of concanavalin-A and tetradecanoylphorbol acetate
on the modulation of parathyroid function by extracellular calcium and
neomycin in dispersed bovine parathyroid cells. Endocrinology 130, 3143–3151.
Brown, E. M., Carroll, R. J., and Aurbach, G. D. (1977b). Dopaminergic
stimulation of cyclic AMP accumulation and parathyroid hormone release
from dispersed bovine parathyroid cells. Proc. Natl. Acad. Sci. U.S.A. 74,
4210–4213. doi: 10.1073/pnas.74.10.4210
Brown, E. M., Enyedi, P., Leboff, M., Rotberg, J., Preston, J., and Chen,
C. (1987). High extracellular Ca2+ and Mg2+ stimulate accumulation of
inositol phosphates in bovine parathyroid cells. FEBS Lett. 218, 113–118.
doi: 10.1016/0014-5793(87)81029-3
Brown, E. M., Fuleihan, G. E., Chen, C. J., and Kifor, O. (1990). A comparison
of the effects of divalent and trivalent cations on parathyroid hormone
release, 3′,5′-cyclic-adenosine monophosphate accumulation, and the levels of
inositol phosphates in bovine parathyroid cells. Endocrinology 127, 1064–1071.
doi: 10.1210/endo-127-3-1064
Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., et al.
(1993). Cloning and characterization of an extracellular Ca2+-sensing receptor
from bovine parathyroid. Nature 366, 575–580. doi: 10.1038/366575a0
Brown, E. M., Gardner, D. G., Windeck, R. A., and Aurbach, G. D. (1978b).
Relationship of intracellular 3′,5′-monophosphate accumulation to parathyroid
hormone release from dispersed bovine parathyroid cells. Endocrinology 103,
2323–2333. doi: 10.1210/endo-103-6-2323
Brown, E. M., Katz, C., Butters, R., and Kifor, O. (1991a). Polyarginine, polylysine,
and protamine mimic the effects of high extracellular calcium concentrations
on dispersed bovine parathyroid cells. J. Bone Miner. Res. 6, 1217–1225.
doi: 10.1002/jbmr.5650061112
Brown, E. M., Leombruno, R., Thatcher, J., and Burrowes, M. (1985). The acute
secretory response to alterations in extracellular calcium concentration and
dopamine in perifused bovine parathyroid cells. Endocrinology 116, 1123–1132.
doi: 10.1210/endo-116-3-1123
Brown, E. M., and MacLeod, R. J. (2001). Extracellular calcium sensing and
extracellular calcium signaling. Physiol. Rev. 81, 239–297.
Brown, E. M., Pollak, M., Seidman, C. E., Seidman, J. G., Chou, Y. H., Riccardi, D.,
et al. (1995). Calcium-ion-sensing cell-surface receptors. N. Engl. J. Med. 333,
234–240. doi: 10.1056/NEJM199507273330407
Canaff, L., and Hendy, G. (2005). Calcium-sensing receptor gene transcription is
up-regulated by the proinflammatory cytokine, interleukin-1beta. Role of the
NF-kappaB PATHWAY and kappaB elements. J. Biol. Chem. 280, 14177–14188.
doi: 10.1074/jbc.M408587200
Canaff, L., and Hendy, G. N. (2002). Human calcium-sensing receptor gene.
Vitamin D response elements in promoters P1 and P2 confer transcriptional
responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem. 277, 30337–30350.
doi: 10.1074/jbc.M201804200
Chang, W., Tu, C., Chen, T. H., Bikle, D., and Shoback, D. (2008). The
extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal
development. Sci. Signal. 1, ra1. doi: 10.1126/scisignal.1159945
Chang, W., Tu, C., Cheng, Z., Rodriguez, L., Chen, T. H., Gassmann, M.,
et al. (2007). Complex formation with the Type B gamma-aminobutyric acid
receptor affects the expression and signal transduction of the extracellular
calcium-sensing receptor. Studies with HEK-293 cells and neurons. J. Biol.
Chem. 282, 25030–25040. doi: 10.1074/jbc.M700924200
Chen, C. J., Barnett, J. V., Congo, D. A., and Brown, E. M. (1989). Divalent cations
suppress 3′,5′-adenosine monophosphate accumulation by stimulating a
pertussis toxin sensitive guanine nucleotide-binding protein in cultured bovine
parathyroid cells. Endocrinology 124, 233–239. doi: 10.1210/endo-124-1-233
Chen, C. J., and Brown, E. M. (1990). The diltiazem analog TA-3090 mimics the
actions of high extracellular Ca2+ on parathyroid function in dispersed bovine
parathyroid cells. J. Bone Miner. Res. 5, 581–587. doi: 10.1002/jbmr.56500
50607
Cheng, Z., Tu, C., Rodriguez, L., Chen, T. H., Dvorak, M. M., Margeta, M.,
et al. (2007). Type B gamma-aminobutyric acid receptors modulate the
function of the extracellular Ca2+-sensing receptor and cell differentiation
in murine growth plate chondrocytes. Endocrinology 148, 4984–4992.
doi: 10.1210/en.2007-0653
Christiansen, B., Hansen, K., Wellendorph, P., and Bräuner-Osborne, H.
(2007). Pharmacological characterization of mouse GPRC6A an, L-
and alpha-amino-acid receptor modulated by divalent cations. Br. J.
Pharmacol. 150, 798–807. doi: 10.1038/sj.bjp.0707121
Chu, Y. W., Pollak, M. R., Brandi, M. L., Toss, G., Arnqvist, H., Atkinson, A. B.,
et al. (1995). Mutations in the human Ca2+-sensing receptor gene that cause
familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56, 1075–1079.
Colloton, M., Shatzen, E., Miller, G., Stehman-Breen, C., Wada, M., Lacey,
D., et al. (2005). Cinacalcet HCl attenuates parathyroid hyperplasia in
a rat model of secondary hyperparathyroidism. Kidney Int. 67, 467–476.
doi: 10.1111/j.1523-1755.2005.67103.x
Conigrave, A. D., and Ward, D. T. (2013). Calcium-sensing receptor (CaSR):
pharmacological properties and signaling pathways. Best Pract. Res. Clin.
Endocrinol. Metab. 27, 315–331. doi: 10.1016/j.beem.2013.05.010
Conigrave, A. D., and Brown, E. M. (2006). L-amino acid-sensing by calcium-
sensing receptors: implications for GI physiology. Am. J. Physiol. 291, G753–
G761.
Conigrave, A. D., Brown, E. M., and Rizzoli, R. (2008). Dietary protein
and bone health: roles of amino acid–sensing receptors in the control of
calcium metabolism and bone homeostasis. Annu. Rev. Nutr. 28, 131–155.
doi: 10.1146/annurev.nutr.28.061807.155328
Conigrave, A. D., Franks, A. H., Brown, E. M., and Quinn, S. J. (2002). L-
Amino acid sensing by the calcium-sensing receptor: a general mechanism for
coupling protein and calcium metabolism? Eur. J. Clin. Nutr. 56, 1072–1080.
doi: 10.1038/sj.ejcn.1601463
Conigrave, A. D., and Hampson, D. R. (2006). Broad-spectrum amino acid sensing
by class 3 G-protein coupled receptors. Trends Endocrinol. Metab. 17, 398–407.
doi: 10.1016/j.tem.2006.10.012
Conigrave, A. D., andHampson, D. R. (2010). Broad-spectrum amino acid-sensing
class C G-protein coupled receptors: molecular mechanisms, physiological
significance and options for drug development. Pharmacol. Ther. 127, 252–260.
doi: 10.1016/j.pharmthera.2010.04.007
Conigrave, A. D., Quinn, S. J., and Brown, E. M. (2000a). Cooperative multi-
modal sensing and therapeutic implications of the extracellular Ca2+-sensing
receptor. Trends Pharm. Sci. 21, 401–407. doi: 10.1016/S0165-6147(00)01546-7
Conigrave, A. D., Quinn, S. J., and Brown, E. M. (2000b). L-amino acid sensing
by the extracellular Ca2+-sensing receptor. Proc. Natl. Acad. Sci. U.S.A. 97,
4814–4819. doi: 10.1073/pnas.97.9.4814
Conigrave, A. D., Mun, H. C., Delbridge, L., Quinn, S. J., Wilkinson, M., and
Brown, E. M. (2004). L-amino acids regulate parathyroid hormone secretion.
J. Biol. Chem. 279, 38151–38159. doi: 10.1074/jbc.M406373200
Conlin, P. R., Fajtova, V. T., Mortensen, R. M., LeBoff, M. S., and Brown, E.
M. (1989). Hysteresis in the relationship between serum ionized calcium
and intact parathyroid hormone during recovery from induced hyper- and
hypocalcemia in normal humans. J. Clin. Endocrinol. Metab. 69, 593–599.
doi: 10.1210/jcem-69-3-593
Corbetta, S., Lania, A., Filopanti, M., Vicentini, L., Ballaré, E., and Spada,
A. (2002). Mitogen-activated protein kinase cascade in human normal
and tumoral parathyroid cells. J. Clin. Endocrinol. Metab. 87, 2201–2205.
doi: 10.1210/jcem.87.5.8492
Daly, K., Al-Rammahi, M., Moran, A., Marcello, M., Ninomiya, Y., and Shirazi-
Beechey, S. P. (2013). Sensing of amino acids by the gut-expressed taste receptor
T1R1-T1R3 stimulates CCK secretion.Am. J. Physiol. Gastrointest Liver Physiol.
304, G271–G282. doi: 10.1152/ajpgi.00074.2012
Davey, A. E., Leach, K., Valant, C., Conigrave, A. D., Sexton, P. M.,
and Christopoulos, A. (2012). Positive and negative allosteric modulators
promote biased signaling at the calcium-sensing receptor. Endocrinology 153,
1232–1241. doi: 10.1210/en.2011-1426
Davies, S. L., Ozawa, A., McCormick, W. D., Dvorak, M. M., and Ward,
D. T. (2007). Protein kinase C-mediated phosphorylation of the calcium-
sensing receptor is stimulated by receptor activation and attenuated by
calyculin-sensitive phosphatase activity. J. Biol. Chem. 282, 15048–15056.
doi: 10.1074/jbc.M607469200
Doré, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M.,
et al. (2014). Structure of class C GPCR metabotropic glutamate receptor 5
transmembrane domain. Nature 511, 557–562. doi: 10.1038/nature13396
Dvorak, M. M., Siddiqua, A., Ward, D. T., Carter, D. H., Dallas, S. L., Nemeth, E.
F., et al. (2004). Physiological changes in extracellular calcium concentration
directly control osteoblast function in the absence of calciotropic hormones.
Proc. Natl. Acad. Sci. U.S.A. 101, 5140–5145. doi: 10.1073/pnas.0306141101
Frontiers in Physiology | www.frontiersin.org 10 December 2016 | Volume 7 | Article 563
Conigrave Role of the CaSR in Parathyroid Function
Egbuna, O. I., and Brown, E. M. (2008). Hypercalcaemic and hypocalcaemic
conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin.
Rheumatol. 22, 129–148. doi: 10.1016/j.berh.2007.11.006
Fitzpatrick, L. A., Brandi, M. L., and Aurbach, G. D. (1986a). Calcium-
controlled secretion is effected through a guanine nucleotide
regulatory protein in parathyroid cells. Endocrinology 119, 2700–2703.
doi: 10.1210/endo-119-6-2700
Fitzpatrick, L. A., Brandi, M. L., and Aurbach, G. D. (1986b). Control of PTH
secretion is mediated through calcium channels and is blocked by pertussis
toxin treatment of parathyroid cells. Biochem. Biophys. Res. Commun. 138,
960–965. doi: 10.1016/S0006-291X(86)80589-7
Fitzpatrick, L. A., Chin, H., Nirenberg, M., and Aurbach, G. D. (1988).
Antibodies to an a-subunit of skeletal muscle calcium channels regulate
parathyroid secretion. Proc. Natl. Acad. Sci. U.S.A. 85, 2115–2119.
doi: 10.1073/pnas.85.7.2115
Fitzpatrick, L. A., Yasumoto, T., and Aurbach, G. D. (1989). Inhibition of
parathyroid hormone release by maitotoxin, a calcium channel activator.
Endocrinology 124, 97–103. doi: 10.1210/endo-124-1-97
Fox, J., and Heath, H. (1981). The “calcium clamp”: effect of constant
hypocalcemia on parathyroid hormone secretion. Am. J. Physiol. 240,
E649–E655.
Gama, L., Wilt, S. G., and Breitwieser, G. E. (2001). Heterodimerization of calcium
sensing receptors with metabotropic glutamate receptors in neurons. J. Biol.
Chem. 276, 39053–39059. doi: 10.1074/jbc.M105662200
Gamba, G., and Friedman, P. A. (2009). Thick ascending limb: the Na+ : K+: 2Cl−
co-transporter, NKCC2, and the calcium-sensing receptor. Pflugers Arch. 458,
61–76. doi: 10.1007/s00424-008-0607-1
Gardner, D. G., Brown, E. M., Attie, M. F., and Aurbach, G. D.
(1980). Prostaglandin-mediated stimulation of adenosine 3′,5′-
monophosphate accumulation and parathyroid hormone release in
dispersed human parathyroid cells. J. Clin. Endocrinol. Metab. 51, 20–25.
doi: 10.1210/jcem-51-1-20
Garrett, J. E., Capuano, I. V., Hammerland, L. J., Hung, B. C. P., Brown, E. M.,
Hebert, S. C., et al. (1995). Molecular cloning and functional expression of
human parathyroid calcium receptor cDNAs. J. Biol. Chem. 270, 12919–12925.
doi: 10.1074/jbc.270.21.12919
Geng, Y., Mosyak, L., Kurinov, I., Zuo, H., Sturchler, E., Cheng, T., et al. (2016).
Structural mechanism of ligand activation in human calcium-sensing receptor.
Elife 5:e13662. doi: 10.7554/eLife.13662
Goltzman, D., and Hendy, G. (2015). The calcium-sensing receptor in bone–
mechanistic and therapeutic insights. Nat. Rev. Endocrinol. 11, 298–307.
doi: 10.1038/nrendo.2015.30
Gorvin, C. M., Cranston, T., Hannan, F. M., Rust, N., Qureshi, A., Nesbit, M. A.,
et al. (2016). A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met,
Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2). J. Bone Miner.
Res. 31, 1200–1206. doi: 10.1002/jbmr.2778
Grant, M. P., Stepanchick, A., and Breitwieser, G. E. (2012). Calcium
signaling regulates trafficking of familial hypocalciuric hypercalcemia (FHH)
mutants of the calcium sensing receptor. Mol. Endocrinol. 26, 2081–2091.
doi: 10.1210/me.2012-1232
Grant, M. P., Stepanchick, A., Cavanaugh, A., and Breitwieser, G. E. (2011).
Agonist-driven maturation and plasma membrane insertion of calcium-
sensing receptors dynamically control signal amplitude. Sci. Signal. 4, ra78.
doi: 10.1126/scisignal.2002208
Hendy, G. N., D’Souza-Li, L., Yang, B., Canaff, L., and Cole, D. E.
(2000). Mutations of the calcium-sensing receptor (CASR) in familial
hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism,
and autosomal dominant hypocalcemia. Hum. Mutat. 16, 281–296.
doi: 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A
Ho, C., Conner, D. A., Pollak, M. R., Ladd, D. J., Kifor, O., Warren,
H. B., et al. (1995). A mouse model of human familial hypocalciuric
hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11,
389–394. doi: 10.1038/ng1295-389
Hough, T. A., Bogani, D., Cheeseman, M. T., Favor, J., Nesbit, M. A.,
Thakker, R. V., et al. (2004). Activating calcium-sensing receptor mutation
in the mouse is associated with cataracts and ectopic calcification.
Proc. Natl. Acad. Sci. U.S.A. 101, 13566–13571. doi: 10.1073/pnas.04055
16101
Huang, C., and Miller, R. T. (2007). The calcium-sensing receptor
and its interacting proteins. J. Cell. Mol. Med. 11, 923–934.
doi: 10.1111/j.1582-4934.2007.00114.x
Imanishi, Y., Kawata, T., Kenko, T., Wada, M., Nagano, N., Miki, T., et al.
(2011). Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid
cell proliferation in a murine model for primary hyperparathyroidism. Calcif.
Tissue Int. 89, 29–35. doi: 10.1007/s00223-011-9490-4
Jiang, Y. F., Zhang, Z., Kifor, O., Lane, C. R., Quinn, S. J., and Bai, M. (2002).
Protein kinase C (PKC) phosphorylation of the Ca2+o-sensing receptor (CaR)
modulates functional interaction of G proteins with the CaR cytoplasmic tail. J.
Biol. Chem. 277, 50543–50549. doi: 10.1074/jbc.M205798200
Kantham, L., Quinn, S. J., Egbuna, O. I., Baxi, K., Butters, R., Pang, J. L., et al.
(2009). The calcium-sensing receptor (CaSR) defends against hypercalcemia
independently of its regulation of parathyroid hormone secretion. Am. J.
Physiol. Endocrinol. Metab. 297, E915–E923. doi: 10.1152/ajpendo.00315.2009
Kemp, E. H., Gavalas, N. G., Akhtar, S., Krohn, K. J., Pallais, J. C., Brown, E. M.,
et al. (2010). Mapping of human autoantibody binding sites on the calcium-
sensing receptor. J. Bone Miner. Res. 25, 132–140. doi: 10.1359/jbmr.090703
Kifor, O., Diaz, R., Butters, R., Kifor, I., and Brown, E. M. (1998). The
calcium-sensing receptor is localized in caveolin-rich plasma membrane
domains of bovine parathyroid cells. J. Biol. Chem. 273, 21708–21713.
doi: 10.1074/jbc.273.34.21708
Kifor, O., MacLeod, R. J., Diaz, R., Bai, M., Yamaguchi, T., Yao, T., et al. (2001).
Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid
and CaR-transfected HEK293 cells. Am. J. Physiol. Renal Physiol. 280, F291–
F302.
Kifor, O., Moore, F. D. Jr., Delaney, M., Garber, J., Hendy, G. N., Butters, R., et al.
(2003). A syndrome of hypocalciuric hypercalcemia caused by autoantibodies
directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88, 60–72.
doi: 10.1210/jc.2002-020249
Kimura, S., Nakagawa, T., Matsuo, Y., Ishida, Y., Okamoto, Y., and
Hayashi, M. (2011). JTT-305, an orally active calcium-sensing receptor
antagonist, stimulates transient parathyroid hormone release and bone
formation in ovariectomized rats. Eur. J. Pharmacol. 668, 331–336.
doi: 10.1016/j.ejphar.2011.07.015
Kubo, Y., Miyashita, T., and Murata, Y. (1998). Structural basis for a Ca2+-sensing
function of the metabotropic glutamate receptors. Science 279, 1722–1725.
doi: 10.1126/science.279.5357.1722
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., et al.
(2000). Structural basis of glutamate recognition by a dimeric metabotropic
glutamate receptor. Nature 407, 971–977. doi: 10.1038/35039564
Lazarus, S., Pretorius, C. J., Khafagi, F., Campion, K. L., Brennan, S.
C., Conigrave, A. D., et al. (2011). A novel mutation of the primary
protein kinase C phosphorylation site in the calcium-sensing receptor
causes autosomal dominant hypocalcemia. Eur. J. Endocrinol. 164, 429–435.
doi: 10.1530/EJE-10-0907
Leach, K., Conigrave, A. D., Sexton, P. M., and Christopoulos, A. (2015). Towards
tissue-specific pharmacology: insights from the calcium-sensing receptor as
a paradigm for GPCR (patho)physiological bias. Trends Pharmacol. Sci. 36,
215–225. doi: 10.1016/j.tips.2015.02.004
Leach, K., Gregory, K. J., Kufareva, I., Khajehali, E., Cook, A. E., Abagyan, R., et al.
(2016). Towards a structural understanding of allosteric drugs at the human
calcium-sensing receptor. Cell Res. 26, 574–592. doi: 10.1038/cr.2016.36
Leach, K., Wen, A., Cook, A. E., Sexton, P. M., Conigrave, A. D., and
Christopoulos, A. (2013). Impact of clinically relevant mutations on the
pharmacoregulation and signaling bias of the calcium-sensing receptor by
positive and negative allosteric modulators. Endocrinology 154, 1105–1116.
doi: 10.1210/en.2012-1887
Loupy, A., Ramakrishnan, S. K., Wootla, B., Chambrey, R., de la Faille, R.,
Bourgeois, S., et al. (2012). PTH-independent regulation of blood calcium
concentration by the calcium-sensing receptor. J. Clin. Invest. 122, 3355–3367.
doi: 10.1172/JCI57407
MacCallum, W. G., Lambert, R. A., and Vogel, K. M. (1914). The removal of
calcium from the blood by dialysis in the study of tetany. J. Exp. Med. 20,
149–168. doi: 10.1084/jem.20.2.149
MacCallum, W. G., and Voegtlin, C. (1909). On the relation of tetany to the
parathyroid glands and to calcium metabolism. J. Exp. Med. 11, 118–151.
doi: 10.1084/jem.11.1.118
Frontiers in Physiology | www.frontiersin.org 11 December 2016 | Volume 7 | Article 563
Conigrave Role of the CaSR in Parathyroid Function
Marx, S. J., Lasker, R. D., Brown, E. M., Fitzpatrick, L. A., Sweezey, N. B.,
Goldbloom, R. B., et al. (1986). Secretory dysfunction in parathyroid cells from
a neonate with severe primary hyperparathyroidism. J. Clin. Endocrinol. Metab.
62, 445–449. doi: 10.1210/jcem-62-2-445
Mayr, B., Glaudo, M., and Schöfl, C. (2016). Activating calcium-sensing receptor
mutations: prospects for future treatment with calcilytics. Trends Endocrinol.
Metab. 27, 643–652. doi: 10.1016/j.tem.2016.05.005
Messa, P., Alfieri, C., and Brezzi, B. (2008). Cinacalcet: pharmacological
and clinical aspects. Expert Opin. Drug Metab. Toxicol. 4, 1551–1560.
doi: 10.1517/17425250802587017
Miller, G., Davis, J., Shatzen, E., Colloton,M., Martin, D., andHenley, C.M. (2012).
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and
reverses established parathyroid gland hyperplasia in a rodent model of CKD.
Nephrol. Dial. Transplant. 27, 2198–2205. doi: 10.1093/ndt/gfr589
Moe, S. M., Cunningham, J., Bommer, J., Adler, S., Rosansky, S. J., Urena-Torres,
P., et al. (2005). Long-term treatment of secondary hyperparathyroidism
with the calcimimetic cinacalcet HCl. Nephrology Dialysis Transplant. 20,
2186–2193. doi: 10.1093/ndt/gfh966
Morrissey, J. J., and Cohn, D. V. (1978). The effects of calcium and
magnesium on the secretion of parathormone and parathyroid secretory
protein by isolated porcine parathyroid cells. Endocrinology 103, 2081–2090.
doi: 10.1210/endo-103-6-2081
Mun, H. C., Brennan, S. C., Delbridge, L., Wilkinson, M., Brown, E. M., and
Conigrave, A. D. (2009). Adenomatous human parathyroid cells exhibit
impaired sensitivity to L-amino acids. J. Clin. Endocrinol. Metab. 94,
3567–3574. doi: 10.1210/jc.2008-2714
Muto, T., Tsuchiya, D., Morikawa, K., and Jingami, H. (2007). Structures of the
extracellular regions of the group II/III metabotropic glutamate receptors. Proc.
Natl. Acad. Sci. U.S.A. 104, 3759–3764. doi: 10.1073/pnas.0611577104
Nemeth, E. F., and Goodman, W. G. (2016). Calcimimetic and calcilytic
drugs: feats, flops, and futures. Calcif. Tissue Int. 98, 341–358.
doi: 10.1007/s00223-015-0052-z
Nemeth, E. F., Heaton, W. H., Miller, M., Fox, J., Balandrin, M. F.,
Van Wagenen, B. C., et al. (2004). Pharmacodynamics of the type II
calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308, 627–635.
doi: 10.1124/jpet.103.057273
Nemeth, E. F. (2006). Misconceptions about calcimimetics. Ann. N.Y Acad. Sci.
1068, 471–476. doi: 10.1196/annals.1346.044
Nemeth, E. F., Delmar, E. G., Heaton,W. L., Miller, M. A., Lambert, L. D., Conklin,
R. L., et al. (2001). Calcilytic compounds: potent and selective Ca2+ receptor
antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp.
Ther. 299, 323–331.
Nemeth, E. F., and Scarpa, A. (1986). Cytosolic Ca2+ and the
regulation of secretion in parathyroid cells. FEBS Lett. 203, 15–19.
doi: 10.1016/0014-5793(86)81427-2
Nemeth, E. F., and Scarpa, A. (1987a). Rapid mobilization of cellular Ca2+ in
bovine parathyroid cells evoked by extracellular divalent cations. Evidence for
a cell surface calcium receptor. J. Biol. Chem. 262, 5188–5196.
Nemeth, E. F., and Scarpa, A. (1987b). “Spermine evokes the rapid mobilization of
cellular Ca2+ in parathyroid cells,” in Calcium-Binding Proteins in Health and
Disease, eds A. W. Norman, T. C. Vanaman, and A. R. Means (San Diego, CA:
Academic Press), 33–35.
Nemeth, E. F., and Shoback, D. (2013). Calcimimetic and calcilytic
drugs. Best Pract. Res. Clin. Endocrinol. Metab. 27, 373–384.
doi: 10.1016/j.beem.2013.02.008
Nemeth, E. F., Steffey, M. E., Hammerland, L. G., Hung, B. C. P., van Wagenen,
B. C., Delmar, E. G., et al. (1998). Calcimimetics with potent and selective
activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 95,
4040–4045. doi: 10.1073/pnas.95.7.4040
Nesbit, M. A., Hannan, F. M., Howles, S. A., Babinsky, V. N., Head, R.
A., Cranston, T., et al. (2013a). Mutations affecting G-protein subunit
α11 in hypercalcemia and hypocalcemia. N.Engl. J. Med. 368, 2476–2486.
doi: 10.1056/NEJMoa1300253
Nesbit, M. A., Hannan, F. M., Howles, S. A., Reed, A. A., Cranston,
T., Thakker, C. E., et al. (2013b). Mutations in AP2S1 cause familial
hypocalciuric hypercalcemia type 3. Nat. Genet. 45, 93–97. doi: 10.1038/ng.
2492
Pallais, J. C., Kifor, O., Chen, Y. B., Slovik, D., and Brown, E. M. (2004). Acquired
hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing
receptor. N. Engl. J. Med. 351, 362–369. doi: 10.1056/NEJMoa040008
Parisi, E., Almadén, Y., Ibarz, M., Panizo, S., Cardús, A., Rodriguez, M., et al.
(2009). N-methyl-D-aspartate receptors are expressed in rat parathyroid gland
and regulate PTH secretion. Am. J. Physiol. Renal Physiol. 296, F1291–F1296.
doi: 10.1152/ajprenal.90557.2008
Peacock, M., Bilezikian, J. P., Bolognese, M. A., Borofsky, M., Scumpia, S.,
Sterling, L. R., et al. (2011). Cinacalcet HCl reduces hypercalcemia in primary
hyperparathyroidism across a wide spectrum of disease severity. J. Clin.
Endocrinol. Metab. 96, E9–E18. doi: 10.1210/jc.2010-1221
Peacock, M., Bilezikian, J. P., Klassen, P. S., Guo, M. D., Turner, S. A., and Shoback,
D. (2005). Cinacalcet hydrochloride maintains long-term normocalcemia in
patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90,
135–141. doi: 10.1210/jc.2004-0842
Pearce, S. H., Williamson, C., Kifor, O., Bai, M., Coulthard, M. G., Davies, M.,
et al. (1996). A familial syndrome of hypocalcemia with hypercalciuria due to
mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115–1122.
doi: 10.1056/NEJM199610103351505
Piret, S. E., Gorvin, C. M., Pagnamenta, A. T., Howles, S. A., Cranston, T., Rust,
N., et al. (2016). Identification of a G-protein subunit-α11 gain-of-function
mutation, Val340Met, in a family with Autosomal Dominant Hypocalcemia
Type 2 (ADH2). J. Bone Miner. Res. 31, 1207–1214. doi: 10.1002/jbmr.2797
Pollak, M. R., Brown, E. M., Chou, Y. W., Hebert, S. C., Marx, S. J., Steinmann, B.,
et al. (1993).Mutations in the humanCa2+-sensing receptor gene cause familial
hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75,
1297–1303. doi: 10.1016/0092-8674(93)90617-Y
Pollak, M. R., Chou, Y. W., Marx, S. J., Steinmann, B., Cole, D. E. C., Brandi,
M. L., et al. (1994). Familial hypocalciuric hypercalcemia and neonatal severe
hyperparathyroidism. Effects of mutant gene dosage on phenotype. J. Clin.
Invest. 93, 1108–1112. doi: 10.1172/JCI117062
Quinn, S. J., Ye, C. P., Diaz, R., Kifor, O., Bai, M., Vassilev, P., et al. (1997). The
Ca2+-sensing receptor: a target for polyamines. Am. J. Physiol. 273(4 Pt 1),
C1315–C1323.
Ray, K., and Northup, J. (2002). Evidence for distinct cation and calcimimetic
compound (NPS 568) recognition domains in the transmembrane
regions of the human Ca2+ receptor. J. Biol. Chem. 277, 18908–18913.
doi: 10.1074/jbc.M202113200
Riccardi, D., and Brown, E. (2010). Physiology and pathophysiology of the
calcium-sensing receptor in the kidney. Am. J. Physiol. Renal Physiol. 298,
F485–F499. doi: 10.1152/ajprenal.00608.2009
Riccardi, D., Park, J., Lee, W. S., Gamba, G., Brown, E. M., and Hebert, S.
C. (1995). Cloning and functional expression of a rat kidney extracellular
calcium/polyvalent cation-sensing receptor. Proc. Natl. Acad. Sci. U.S.A. 92,
131–135. doi: 10.1073/pnas.92.1.131
Riccardi, D., Traebert, M., Ward, D. T., Kaissling, B., Biber, J., Hebert, S.
C., et al. (2000). Dietary phosphate and parathyroid hormone alter the
expression of the calcium-sensing receptor (CaR) and the Na+-dependent Pi
transporter (NaPi-2) in the rat proximal tubule. Pflugers Arch. 441, 379–387.
doi: 10.1007/s004240000436
Riccardi, D., and Valenti, G. (2016). Localization and function of the renal calcium-
sensing receptor. Nat. Rev. Nephrol. 12, 414–425. doi: 10.1038/nrneph.2016.59
Richard, C., Huo, R., Samadfam, R., Bolivar, I., Miao, D., Brown, E., et al. (2010).
The calcium-sensing receptor and 25-hydroxyvitamin D-1alpha-hydroxylase
interact to modulate skeletal growth and bone turnover. J. Bone Miner. Res.
25, 1627–1636. doi: 10.1002/jbmr.58
Ritter, C. S., Haughey, B. H., Miller, B., and Brown, A. J. (2012). Differential gene
expression by oxyphil and chief cells of human parathyroid glands. J. Clin.
Endocrinol. Metab. 97, E1499–E1505. doi: 10.1210/jc.2011-3366
Ruat, M., Molliver, M. E., Snowman, A. M., and Snyder, S. H. (1995). Calcium-
sensing receptor: molecular cloning in rat and localization to nerve terminals.
Proc. Natl. Acad. Sci. U.S.A. 92, 3161–3165. doi: 10.1073/pnas.92.8.3161
Salinger, E. M., and Moore, J. T. (2013). Perioperative indicators of hypocalcemia
in total thyroidectomy: the role of vitamin D and parathyroid hormone. Am. J.
Surg. 206, 876–881. doi: 10.1016/j.amjsurg.2013.08.020
Santa Maria, C., Cheng, Z., Li, A., Wang, J., Shoback, D., Tu, C., et al.
(2016). Interplay between CaSR and PTH1R signaling in skeletal
Frontiers in Physiology | www.frontiersin.org 12 December 2016 | Volume 7 | Article 563
Conigrave Role of the CaSR in Parathyroid Function
development and osteoanabolism. Semin. Cell Dev. Biol. 49, 11–23.
doi: 10.1016/j.semcdb.2015.12.004
Schwarz, P., Sørensen, H. A., Transbøl, I., and McNair, P. (1992). Regulation of
acute parathyroid hormone release in normal humans: combined calcium and
citrate clamp study. Am. J. Physiol. 263, E195–E198.
Shoback, D. M., Membreno, L. A., and McGhee, J. G. (1988). High calcium and
other divalent cations increase inositol trisphosphate in bovine parathyroid
cells. Endocrinology 123, 382–389. doi: 10.1210/endo-123-1-382
Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, M., Dusso, A., et al. (1996).
Phosphorus restriction prevents parathyroid gland growth. High phosphorus
directly stimulates PTH secretion in vitro. J. Clin Invest. 97, 2534–2540.
doi: 10.1172/JCI118701
Tan, Y. M., Cardinal, J., Franks, A. H., Mun, H. C., Lewis, N., Harris, L. B.,
et al. (2003). Autosomal dominant hypocalcemia: a novel activating mutation
(E604K) in the cysteine-rich domain of the calcium-sensing receptor. J. Clin.
Endocrinol. Metab. 88, 605–610. doi: 10.1210/jc.2002-020081
Tatsumi, R., Komaba, H., Kanai, G., Miyakogawa, T., Sawada, K., Kakuta, T.,
et al. (2013). Cinacalcet induces apoptosis in parathyroid cells in patients with
secondary hyperparathyroidism: histological and cytological analyses.Nephron
Clin. Pract. 124, 224–231. doi: 10.1159/000357951
Tfelt-Hansen, J., MacLeod, R. J., Chattopadhyay, N., Yano, S., Quinn, S., Ren,
X., et al. (2003). Calcium-sensing receptor stimulates PTHrP release by
pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells.
Am. J. Physiol. Endocrinol. Metab. 285, E329–E337. doi: 10.1152/ajpendo.004
89.2002
Thakker, R. V. (2004). Diseases associated with the extracellular calcium-
sensing receptor. Cell Calcium 35, 275–282. doi: 10.1016/j.ceca.2003.
10.010
Tsuchiya, D., Kunishima, N., Kamiya, N., Jingami, H., and Morikawa, K. (2002).
Structural views of the ligand-binding cores of a metabotropic glutamate
receptor complexed with an antagonist and both glutamate and Gd3+. Proc.
Natl. Acad. Sci. U.S.A. 99, 2660–2665. doi: 10.1073/pnas.052708599
Vasher, M., Goodman, A., Politz, D., and Norman, J. (2010). Postoperative calcium
requirements in 6,000 patients undergoing outpatient parathyroidectomy:
easily avoiding symptomatic hypocalcemia. J. Am. Coll. Surg. 211, 49–54.
doi: 10.1016/j.jamcollsurg.2010.03.019
Walter, S., Baruch, A., Dong, J., Tomlinson, J. E., Alexander, S. T., Janes, J.,
et al. (2013). Pharmacology of AMG 416 (Velcalcetide), a novel peptide
agonist of the calcium-sensing receptor, for the treatment of secondary
hyperparathyroidism in hemodialysis patients. J. Pharmacol. Exp. Ther. 346,
229–240. doi: 10.1124/jpet.113.204834
Ward, B. K., Magno, A. L., Davis, E. A., Hanyaloglu, A. C., Stuckey, B. G. A.,
Burrows, M., et al. (2004). Functional deletion of the calcium-sensing receptor
in a case of neonatal severe hyperparathyroidism. J. Clin. Endocrinol. Metab. 89,
3721–3730. doi: 10.1210/jc.2003-031653
Westerdahl, J., Lindblom, P., Valdemarsson, S., Tibblin, S., and
Bergenfelz, A. (2000). Risk factors for postoperative hypocalcemia after
surgery for primary hyperparathyroidism. Arch. Surg. 135, 142–147.
doi: 10.1001/archsurg.135.2.142
Wettschureck, N., Lee, E., Libutti, S. K., Offermanns, S., Robey, P. G., and
Spiegel, A. M. (2007). Parathyroid-specific double knockout of Gq and
G11 alpha-subunits leads to a phenotype resembling germline knockout
of the extracellular Ca2+-sensing receptor. Mol. Endocrinol. 21, 274–280.
doi: 10.1210/me.2006-0110
Windeck, R., Brown, E. M., Gardner, D. G., and Aurbach, G. D. (1978). Effect of
gastrointestinal hormones on isolated bovine parathyroid cells. Endocrinology
103, 2020–2026. doi: 10.1210/endo-103-6-2020
Wise, A., Green, A., Main, M. J., Wilson, R., Fraser, N., and Marshall, F. H. (1999).
Calcium sensing properties of the GABAB receptor. Neuropharmacology 38,
1647–1656. doi: 10.1016/S0028-3908(99)00119-7
Ye, C., Ho-Pao, C. L., Kanazirska, M., Quinn, S., Rogers, K., Seidman, C. E.,
et al. (1997). Amyloid-beta proteins activate Ca2+-permeable channels through
calcium-sensing receptors. J. Neurosci. Res. 47, 547–554.
Young, S. H., Rey, O., Sinnett-Smith, J., and Rozengurt, E. (2014). Intracellular
Ca2+ oscillations generated via the Ca2+-sensing receptor are mediated by
negative feedback by PKCα at Thr888. Am. J. Physiol. Cell Physiol. 306, C298–
C306. doi: 10.1152/ajpcell.00194.2013
Zhang, C., Zhang, T., Zou, J., Miller, C. L., Gorkhali, R., Yang, J. Y., et al.
(2016). Structural basis for regulation of human calcium-sensing receptor by
magnesium ions and an unexpected tryptophan derivative co-agonist. Sci Adv.
2:e1600241. doi: 10.1126/sciadv.1600241
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Conigrave. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 13 December 2016 | Volume 7 | Article 563
